- Home
- VOR vs CLPS Comparison
VOR vs CLPS Comparison
Compare VOR & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOR
- CLPS
- Stock Information
- Founded
- VOR 2015
- CLPS 2005
- Country
- VOR United States
- CLPS Hong Kong
- Employees
- VOR N/A
- CLPS N/A
- Industry
- VOR Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- VOR Health Care
- CLPS Technology
- Exchange
- VOR Nasdaq
- CLPS Nasdaq
- Market Cap
- VOR 22.1M
- CLPS 26.3M
- IPO Year
- VOR 2021
- CLPS 2018
- Fundamental
- Price
- VOR $0.20
- CLPS $0.95
- Analyst Decision
- VOR Buy
- CLPS
- Analyst Count
- VOR 6
- CLPS 0
- Target Price
- VOR $7.20
- CLPS N/A
- AVG Volume (30 Days)
- VOR 5.4M
- CLPS 8.9K
- Earning Date
- VOR 05-14-2025
- CLPS 03-05-2025
- Dividend Yield
- VOR N/A
- CLPS 13.69%
- EPS Growth
- VOR N/A
- CLPS N/A
- EPS
- VOR N/A
- CLPS N/A
- Revenue
- VOR N/A
- CLPS $153,816,045.00
- Revenue This Year
- VOR N/A
- CLPS N/A
- Revenue Next Year
- VOR N/A
- CLPS N/A
- P/E Ratio
- VOR N/A
- CLPS N/A
- Revenue Growth
- VOR N/A
- CLPS 5.81
- 52 Week Low
- VOR $0.13
- CLPS $0.68
- 52 Week High
- VOR $1.80
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- VOR 26.80
- CLPS 43.14
- Support Level
- VOR $0.17
- CLPS $0.94
- Resistance Level
- VOR $0.20
- CLPS $1.05
- Average True Range (ATR)
- VOR 0.03
- CLPS 0.05
- MACD
- VOR 0.02
- CLPS 0.00
- Stochastic Oscillator
- VOR 38.76
- CLPS 19.93
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.